{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T23:07:16Z","timestamp":1791068836474,"version":"4.1.0"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2012,1,26]],"date-time":"2012-01-26T00:00:00Z","timestamp":1327536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Career Development Award from the Dermatology Foundation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background.<\/jats:title>\n                  <jats:p>Bevacizumab, a monoclonal antibody targeting a vascular endothelial growth factor (VEGF) protein, has been reported to induce mucosal toxicities. However, the clinical characteristics of these particular toxicities have not been well characterized. We aimed at providing a detailed clinical description of signs and symptoms limited to the tongue mucosa in patients treated with bevacizumab.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods.<\/jats:title>\n                  <jats:p>A retrospective review of medical records and clinical photographs was performed with specific attention to clinical presentation, evolution, associated symptoms, concomitant medications, and treatment methods.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results.<\/jats:title>\n                  <jats:p>In total, four patients presented to the dermatology service with clinical findings characterized by multifocal, erythematous circinate and serpiginous erosions on the dorsal tongue surrounded by white hyperkeratotic rims that were temporally related to bevacizumab therapy. Associated increased sensitivity to spicy foods was frequently observed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion.<\/jats:title>\n                  <jats:p>These characteristic clinical findings are consistent with geographic tongue. However, large prospective evaluations are necessary to confirm this potential relationship. If bevacizumab is indeed associated with geographic tongue, increased awareness may result in improved reporting and characterization of this particular adverse event.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1634\/theoncologist.2011-0198","type":"journal-article","created":{"date-parts":[[2012,1,27]],"date-time":"2012-01-27T03:11:33Z","timestamp":1327633893000},"page":"274-278","source":"Crossref","is-referenced-by-count":32,"title":["Characteristics of Oral Mucosal Events Related to Bevacizumab Treatment"],"prefix":"10.1093","volume":"17","author":[{"given":"Igor T.","family":"Gavrilovic","sequence":"first","affiliation":[{"name":"a Department of Neurology, Memorial Sloan-Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yevgeniy","family":"Balagula","sequence":"additional","affiliation":[{"name":"b Dermatology Service, Memorial Sloan-Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyx C.","family":"Rosen","sequence":"additional","affiliation":[{"name":"b Dermatology Service, Memorial Sloan-Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay","family":"Ramaswamy","sequence":"additional","affiliation":[{"name":"c Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maura N.","family":"Dickler","sequence":"additional","affiliation":[{"name":"d Breast Cancer Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira J.","family":"Dunkel","sequence":"additional","affiliation":[{"name":"c Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario E.","family":"Lacouture","sequence":"additional","affiliation":[{"name":"b Dermatology Service, Memorial Sloan-Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,1,26]]},"reference":[{"key":"2021122308120003900_B1","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1634\/theoncologist.2009-0121","article-title":"FDA drug approval summary: Bevacizumab (Avastin) as treatment of recurrent glioblastoma multiforme","volume":"14","author":"Cohen","year":"2009","journal-title":"The Oncologist"},{"key":"2021122308120003900_B2","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3174\/ajnr.A1987","article-title":"Bevacizumab (Avastin)","volume":"31","author":"Mukherji","year":"2010","journal-title":"AJNR Am J Neuroradiol"},{"key":"2021122308120003900_B3","volume-title":"FDA Approval for Bevacizumab"},{"key":"2021122308120003900_B4","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrclinonc.2009.94","article-title":"Adverse effects of anticancer agents that target the VEGF pathway","volume":"6","author":"Chen","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"2021122308120003900_B5","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.eururo.2011.01.002","article-title":"Toxicities of targeted therapy and their management in kidney cancer","volume":"59","author":"Di Lorenzo","year":"2011","journal-title":"Eur Urol"},{"key":"2021122308120003900_B6","first-page":"272","article-title":"Wandering rash of the tongue (geographic tongue)","volume":"69","author":"Prinz","year":"1927","journal-title":"Dent Cosmos"},{"key":"2021122308120003900_B7","first-page":"113","article-title":"Migratory glossitis. A clinical-histologic review of seventy cases","volume":"39","author":"B\u00e0n\u00f3czy","year":"1975","journal-title":"Oral Surg Oral Med Oral Pathol"},{"key":"2021122308120003900_B8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0300-5712(75)90020-2","article-title":"Geographic stomatitis: A critical review","volume":"3","author":"Hume","year":"1975","journal-title":"J Dent"},{"key":"2021122308120003900_B9","doi-asserted-by":"crossref","first-page":"223","DOI":"10.4065\/74.3.223","article-title":"Clinical assessment and outcome in 70 patients with complaints of burning or sore mouth symptoms","volume":"74","author":"Drage","year":"1999","journal-title":"Mayo Clin Proc"},{"key":"2021122308120003900_B10","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1111\/j.1468-3083.2004.01032.x","article-title":"Painful geographic tongue (benign migratory glossitis) in a child","volume":"18","author":"Menni","year":"2004","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2021122308120003900_B11","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/j.1346-8138.2007.00284.x","article-title":"Successful treatment with cyclosporin administration for persistent benign migratory glossitis","volume":"34","author":"Abe","year":"2007","journal-title":"J Dermatol"},{"key":"2021122308120003900_B12","first-page":"627","article-title":"Common tongue conditions in primary care","volume":"81","author":"Reamy","year":"2010","journal-title":"Am Fam Physician"},{"key":"2021122308120003900_B13","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1016\/j.oraloncology.2011.03.028","article-title":"Oral complications of targeted cancer therapies: A narrative literature review","volume":"47","author":"Watters","year":"2011","journal-title":"Oral Oncol"},{"key":"2021122308120003900_B14","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/S0002-9343(02)01379-7","article-title":"Benign migratory glossitis or geographic tongue: An enigmatic oral lesion","volume":"113","author":"Assimakopoulos","year":"2002","journal-title":"Am J Med"},{"key":"2021122308120003900_B15","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1159\/000079590","article-title":"Prevalence of fissured tongue, geographic tongue and median rhomboid glossitis among Israeli adults of different ethnic origins","volume":"209","author":"Yarom","year":"2004","journal-title":"Dermatology"},{"key":"2021122308120003900_B16","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.1601-0825.2005.01208.x","article-title":"Prevalence and risk factors associated with geographic tongue among US adults","volume":"12","author":"Shulman","year":"2006","journal-title":"Oral Dis"},{"key":"2021122308120003900_B17","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/j.1365-4362.1992.tb03966.x","article-title":"Geographic tongue developing in a patient on lithium carbonate therapy","volume":"31","author":"Patki","year":"1992","journal-title":"Int J Dermatol"},{"key":"2021122308120003900_B18","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1097\/00004583-199909000-00005","article-title":"Lithium and geographic tongue","volume":"38","author":"Gracious","year":"1999","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"2021122308120003900_B19","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1002\/(SICI)1096-9896(1998100)186:2<186::AID-PATH148>3.0.CO;2-J","article-title":"Vascular endothelial growth factor is constitutively expressed in normal human salivary glands and is secreted in the saliva of healthy individuals","volume":"186","author":"Pammer","year":"1998","journal-title":"J Pathol"},{"key":"2021122308120003900_B20","first-page":"959","article-title":"[A retrospective study of oral adverse events with colorectal cancer chemotherapy using bevacizumab]","volume":"38","author":"Takahashi","year":"2011","journal-title":"Gan To Kagaku Ryoho"},{"key":"2021122308120003900_B21","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1200\/JCO.2008.21.6457","article-title":"Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer","volume":"28","author":"Miles","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122308120003900_B22","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N Engl J Med"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2011-0198","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2011-0198","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/17\/2\/274\/41860067\/oncolo_17_2_274.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/17\/2\/274\/41860067\/oncolo_17_2_274.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T19:34:54Z","timestamp":1640288094000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/17\/2\/274\/6403334"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,26]]},"references-count":22,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2012,1,26]]},"published-print":{"date-parts":[[2012,2,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2011-0198","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2012,2,1]]},"published":{"date-parts":[[2012,1,26]]}}}